CCM
LGND icon

Catapult Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Catapult Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-8,015
Closed -$505K – 188
2015
Q2 		$505K Sell
8,015
-8,015
-50% -$437K 0.07% 199
2015
Q1 		$771K Buy
+16,030
New +$614K 0.09% 178

Other funds holding LGND

RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Catapult Capital Management's LGND Position: Q3 2015 in Review

Catapult Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2015, closing a stake of 8,015 shares — an estimated $505K sold.

Catapult Capital Management first reported a position in LGND in Q1 2015 and held it in 2 quarters. The position peaked at $771K in Q1 2015. 203 funds tracked by Wall St. Rank hold LGND as of Q3 2015.

  • Catapult Capital Management reported no remaining Ligand Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Catapult Capital Management sold 8,015 Ligand Pharmaceuticals shares in Q3 2015, an estimated $505K.
  • Catapult Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Catapult Capital Management's Ligand Pharmaceuticals position peaked at $771K in Q1 2015.
  • 203 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2015.

Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.